

To
BSE Ltd.
P.J. Towers, Dalal Street,
Mumbai - 400 001.

Script Code : **524731**

Sub.: Outcome of Board Meeting held today, i.e. 06th August, 2026 - standalone Unaudited Financial Results of the Company for the Quarter ended on 30th June, 2026.

Reg.: Regulation 30(2) and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015.

Dear Sir,

Kindly note that the Audit Committee have reviewed and the Board of Directors of the Company have approved the standalone unaudited financial results of the Company for the quarter from 1st April, 2026 to 30th June, 2026, during their respective meetings held today, i.e. on 06th August, 2026.

The said standalone unaudited financial results for the quarter from 1st April, 2026 to 30th June, 2026, duly signed in the format specified under regulation 33(4) of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, is enclosed.

Also, enclosed alongwith is the limited audit review report of the auditors of the Company, on the standalone unaudited financial results for the quarter ended on 30th June, 2026.

The Board Meeting commenced at 02.30 p.m. (IST) and concluded at 5:40 p.m. (IST) on 06th August, 2026.

Kindly take on record the above and acknowledge.

Thanking you,

Yours faithfully,
For Jenburkt Pharmaceuticals Limited,

(ASHISH R. SHAH)
Sr. VP and Company Secretary and Compliance Officer.



Statement of Standalone Unaudited Financial Results for the Quarter Ended on 30th June, 2026

(₹. in Lacs other than EPS)

	Particulars	Quarter Ended			Year Ended
		30-06-2026	31-03-2026	30-06-2025	31-03-2026
		Unaudited	Audited	Unaudited	Audited
I	Revenue from Operations	3551.20	4463.23	3552.68	16874.06
II	Other Income	151.32	434.83	205.71	1029.94
III	Total income (I + II)	3702.52	4898.06	3758.39	17904.00
IV	Expenses				
	(a) Cost of Materials Consumed	231.59	219.35	213.54	899.35
	(b) Purchase of Stock-in-trade	547.84	869.61	537.24	2817.89
	(c) Changes in inventories of Finished Goods, Stock-in-trade and WIP	-147.24	-222.68	-99.02	-484.67
	(d) Employee benefit expenses	1302.52	951.53	1172.08	4988.22
	(e) Finance Costs	13.02	12.92	10.99	46.20
	(f) Depreciation and Amortisation Expense	64.07	80.88	72.25	310.76
	(g) Other expenses	1013.81	1220.52	833.11	4279.25
	Total Expenses (IV)	3025.61	3132.13	2740.19	12857.00
V	Profit before exceptional items and tax (III-IV)	676.91	1765.93	1018.20	5047.00
VI	Exceptional items				
	Impact of Labour Codes #	0.00	395.11	0.00	395.11
VII	Profit before tax (V-VI)	676.91	1370.82	1018.20	4651.89
VIII	Tax Expense				
	(i) Current Tax	100.00	360.00	200.00	1260.00
	(ii) Income Tax for previous years	0.00	4.10	0.00	4.10
	(iii) Deferred Tax	-11.65	-78.23	39.02	-85.81
IX	Profit/(Loss) after Tax (VII-VIII)	588.56	1084.95	779.18	3473.60
X	Other Comprehensive Income				
A	(i) Items that will not be reclassified to profit or loss	163.76	-347.92	155.19	-171.20
	(ii) Income Tax relating to Items that will not be reclassified to profit or loss	-13.51	26.51	-17.76	18.30
B	(i) Items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00
	(ii) Income Tax relating to Items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00
XI	Total Comprehensive Income for the period (IX+X)	738.81	763.54	916.61	3320.70
	Paid up Equity Share Capital (F.V. Rs.10/- each)	441.33	441.33	441.33	441.33
XII	Earnings Per Share (in Rs.) (F.V. Rs.10/-) Basic and Diluted	13.34	24.58	17.66	78.71

Notes:


- The above statement of standalone unaudited financial results were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their respective meetings held on 6th August, 2026.
- The Company is dealing exclusively in Pharmaceuticals business segment, hence segment wise reporting is not applicable.
- # The Government of India notified the Revised Labour Codes on November 21, 2025, resulting in an increase of ₹395.11 lakhs in gratuity and leave liabilities due to past service costs arising from plan amendments in FY 2025-26.

Place : Mumbai

Date : 6th August, 2026



For Jenburkt Pharmaceuticals Limited


 (Ashish U. Bhuta)

Chairman & Managing Director


 (DIN No: 00226479)

Science hai toh Hope hai Hope hai toh Health hai Health hai toh Happiness hai

D.R.MEHTA & ASSOCIATES

(CHARTERED ACCOUNTANTS)

H-2, EVEREST BUILDING, 9TH FLOOR, TARDEO CIRCLE, MUMBAI - 400034

TEL: 23513758 / 23520330 FAX: 66607263, 9322508373

Email ID: info@drmehta.in, vikram@drmehta.in, ashok@drmehta.in

Limited Review Report on Unaudited Quarterly Standalone Financial Results of Jenburkt Pharmaceuticals Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015

To the Board of Directors of

Jenburkt Pharmaceuticals Limited

We have reviewed the accompanying statement of unaudited standalone financial results of JENBURKT PHARMACEUTICALS LTD for the quarter ended 30th June 2026 (the statement).

This statement is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Our conclusion is not modified in respect of this matter.

For D.R.Mehta & Associates,
Chartered Accountants
(Firm Reg. No. 106207W)



Partner

Vikram Mehta

(Membership No. 047347)

UDIN: 26047347EMR2JPH6651

Place: Mumbai

Date: 6th August 2026

